ITM Isotope Technologies Munich and the Paul Scherrer Institute plan to co-develop the radionuclide terbium-161 (Tb-161) for cancer therapy.
The companies will combine their respective technologies and expertise toward developing a large-scale production process for Tb-161, which has shown promise in preliminary studies as a therapeutic radionuclide in prostate cancer.
This collaboration significantly expands ITM's production and development portfolio for medical isotopes in precision oncology, ITM said in a news release.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
